BIIB Jan 2025 110.000 put
| Previous close | 1.2500 |
| Open | 1.2500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 110.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.2500 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireFDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.
Motley FoolIs Biogen Stock a Buy Now?
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.
ZacksIonis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
